In this regard, many studies have reported that both the Raf/MEK/MAPK and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways together promote the resistance of cancer cells to gefitinib (11,12). This evidence concerns the gene AKT1 and cancer.